2105.09.13晚期大肠癌一线治疗报告范本.ppt

* CAIRO3 ： Phase III 贝伐珠单抗 with Xeloda and oxaliplatin (induction therapy) followed by 贝伐珠单抗 with Xeloda vs observation in first-line metastatic colorectal cancer (randomized) (CAIRO3) Induction therapy (6 cycles):贝伐珠单抗: 7.5 mg/kg via IV infusion d1 Q3WXeloda: 1000 mg/m2 bid d1-14 Q3W (patients with moderate renal impairment will receive 750 mg/m2 bid)oxaliplatin: 130 mg/m2 via IV infusion d1 Q3W Maintenance therapy:贝伐珠单抗: 7.5 mg/kg via IV infusion d1 Q3WXeloda: 625 mg/m2 bid given daily continuously until PD, toxicity or patient withdrawal Secondary outcomes include PFS after random